Key Takeaways CorMedix launched DefenCath in 2024, generating $78.8M in H1 2025 revenues and raising guidance.CRMD acquired Melinta for$300M, adding seven marketed therapies and diversifying beyond DefenCath.MIRM's Livmarli posted $161.4M H1 2025 sales, but revenue reliance and competition pose key risks.CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) are pursuing treatments for underserved medical conditions where existing therapies are limited or nonexistent. Both companies are carving out niches in are ...